Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.

Thomas PrebetJacques DelaunayEric WattelThorsten BraunPascale Cony-MakhoulSophie DimicoliStephan WickenhauserJulie LejeuneSylvie ChevretFatiha ChermatPierre FenauxNorbert Veynull null

Published in: British journal of haematology (2016)

Keyphrases

phase ii
acute myeloid leukemia
clinical trial
open label
randomized controlled trial
double blind